Company: HRTX
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0000950170-25-060882
Chunk: 0

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

| Filed by the Registrant ☒ | Filed by a party other than the Registrant ☐ |

Check the appropriate box:

| ☐ |     | Preliminary Proxy Statement                                                     |
| ☐ |     | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☒ |     | Definitive Proxy Statement                                                      |
| ☐ |     | Definitive Additional Materials                                                 |
| ☐ |     | Soliciting Material Pursuant to §240.14a-12                                     |

HERON THERAPEUTICS, INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply):

| ☒ |     | No fee required                                                                                     |
| ☐ |     | Fee paid previously with preliminary materials                                                      |
| ☐ |     | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |

HERON THERAPEUTICS, INC. Notice of 2025 Annual Meeting of Stockholders to Be Held on June 12, 2025 To the Stockholders of Heron Therapeutics, Inc.: The 2025 Annual Meeting of Stockholders of Heron Therapeutics, Inc., a Delaware corporation (“ Heron ,” “ Company ,” “ we ,” “ us ” and “ our ”), will be held on June 12, 2025 at 9:00 a.m. Eastern Time exclusively by means of remote communication via the Internet at www.virtualshareholdermeeting.com/HRTX2025 , or at any adjournments or postponements thereof (the “ Annual Meeting ”), for the following purposes, as more fully described in the enclosed Proxy Statement: 1. To elect six director nominees named in the enclosed Proxy Statement to serve until the 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal; 2. To ratify the appointment of Withum Smith+Brown, PC (“ Withum ”) as our independent registered public accounting firm